Pfizer released Phase 2b data showing its Metsera-originated monthly GLP-1 delivered clinically meaningful weight loss and glycemic control. The company reported up to 10.5% mean body-weight reduction at six months with the monthly formulation and highlighted continued weight loss after patients switched to monthly dosing in extension analyses. Pfizer frames the results as validation of its roughly $10 billion acquisition of Metsera and as evidence that an extended‑interval delivery of GLP-1 receptor agonists can maintain metabolic efficacy. For large pharma and competitors, the data both confirm the commercial potential of longer-acting GLP-1 formats and sharpen competition among next-generation obesity and diabetes therapies.